Skip to main content

Research Repository

Advanced Search

Moxidectin: an oral treatment for human onchocerciasis

Milton, P; Hamley, JID; Walker, M; Basáñez, MG


P Milton

JID Hamley

M Walker

MG Basáñez


Moxidectin is a milbemycin endectocide recently approved for the treatment of human onchocerciasis. Onchocerciasis, earmarked for elimination of transmission, is a filarial infection endemic in Africa, Yemen, and the Amazonian focus straddling Venezuela and Brazil. Concerns over whether the predominant treatment strategy (yearly mass drug administration (MDA) of ivermectin) is sufficient to achieve elimination in all endemic foci have refocussed attention upon alternative treatments. Moxidectin’s stronger and longer microfilarial suppression compared to ivermectin in both phase II and III clinical trials indicates its potential as a novel powerful drug for onchocerciasis elimination.


Milton, P., Hamley, J., Walker, M., & Basáñez, M. (2020). Moxidectin: an oral treatment for human onchocerciasis. Expert Review of Anti-infective Therapy, 1-15.

Journal Article Type Article
Acceptance Date Jul 3, 2020
Publication Date Jul 26, 2020
Deposit Date Aug 14, 2020
Publicly Available Date Aug 14, 2020
Journal Expert Review of Anti-infective Therapy
Print ISSN 1478-7210
Publisher Taylor and Francis
Peer Reviewed Peer Reviewed
Pages 1-15
Public URL
Publisher URL


Downloadable Citations